- Home
- CNX vs JAZZ Comparison
CNX vs JAZZ Comparison
Compare CNX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | JAZZ |
|---|---|---|
| Founded | 1860 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 16.1B |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CNX | JAZZ |
|---|---|---|
| Price | $33.04 | $234.49 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $35.71 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.5M | 836.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | 3.56 | ★ 7.17 |
| Revenue | ★ $2,239,134,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | $11.14 | $7.68 |
| P/E Ratio | ★ $9.27 | $32.76 |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $31.47 | $125.79 |
| 52 Week High | $43.62 | $266.38 |
Technical Indicators
Market Signals| Indicator | CNX | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.40 | 37.90 |
| Support Level | $32.83 | $222.49 |
| Resistance Level | $34.38 | $242.66 |
| Average True Range (ATR) | 0.92 | 4.77 |
| MACD | -0.41 | -0.88 |
| Stochastic Oscillator | 14.17 | 15.48 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.